Taking thalidomide out of rehab

被引：13

作者：

Akhurst, Rosemary J. ^{[1
,2
]}

机构：

[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

[2] Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA

来源：

NATURE MEDICINE | 2010年 / 16卷 / 04期

关键词：

HEREDITARY HEMORRHAGIC TELANGIECTASIA; GROWTH-FACTOR-BETA; ANGIOGENESIS; MICE; BEVACIZUMAB; DEFECTS; VEGF;

D O I：

10.1038/nm0410-370

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Thalidomide, a drug reviled in the 1960s for its teratogenic effects, has been revived in recent years for cancer and leprosy therapy. A study now finds another use for this drug in vascular disease, providing further insights into the drug's mechanisms of action (pages 420-428).

引用

收藏

页码：370 / 372

页数：4

相关论文

共 13 条

[1] Potential role of modifier genes influencing transforming growth factor-β1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia [J].

Bourdeau, A ;

Faughnan, ME ;

McDonald, ML ;

Paterson, AD ;

Wanless, IR ;

Letarte, M .

AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (06) :2011-2020

[2] THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS [J].

DAMATO, RJ ;

LOUGHNAN, MS ;

FLYNN, E ;

FOLKMAN, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :4082-4085

[3]

DANIEL TO, 1987, J BIOL CHEM, V262, P11893

[4]

DEEKEN JF, 2009, PHARMACOGENOMIC 1229, P29, DOI DOI 10.1038/TPJ.2009.57

[5] Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab [J].

Flieger, Dimitri ;

Hainke, Sabine ;

Fischbach, Wolfgang .

ANNALS OF HEMATOLOGY, 2006, 85 (09) :631-632

[6] Gap junction communication mediates transforming growth factor-β activation and endothelial-induced mural cell differentiation [J].

Hirschi, KK ;

Burt, JM ;

Hirschi, KD ;

Dai, CP .

CIRCULATION RESEARCH, 2003, 93 (05) :429-437

[7] Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia [J].

Lebrin, Franck ;

Srun, Samly ;

Raymond, Karine ;

Martin, Sabrina ;

van den Brink, Stieneke ;

Freitas, Catarina ;

Breant, Christiane ;

Mathivet, Thomas ;

Larrivee, Bruno ;

Thomas, Jean-Leon ;

Arthur, Helen M. ;

Westermann, Cornelis J. J. ;

Disch, Frans ;

Mager, Johannes J. ;

Snijder, Repke J. ;

Eichmann, Anne ;

Mummery, Christine L. .

NATURE MEDICINE, 2010, 16 (04) :420-U101

[8]

Li XP, 2003, ANTICANCER RES, V23, P2481

[9] Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia [J].

Mitchell, Andrew ;

Adams, Leon A. ;

Mac Uillan, Gerry ;

Tibballs, Jon ;

Driesen, Rohan Vanden ;

Delriviere, Luc .

LIVER TRANSPLANTATION, 2008, 14 (02) :210-213

[10] Genetic loci that control vascular endothelial growth factor-induced angiogenesis [J].

Rogers, MS ;

Rohan, RM ;

Birsner, AE ;

D'Amato, RJ .

FASEB JOURNAL, 2003, 17 (12) :2112-+